Keeping up with new data and applying up-to-date information in treating patients with cancer has been identified by healthcare professionals as the biggest challenge in the treatment of hematologic and oncologic disorders. Featuring a faculty of internationally recognized experts, the CTCA REVIEW online webcasts highlight cutting-edge research and clinical studies presented during recent American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) annual meetings. As highlights from the annual CTCA REVIEW, a live review course hosted by the Cancer Treatment Centers of America, the course material has been divided into two online activities. This online activity highlights Oncology/Solid Tumor content. A second online activity highlights Hematology/Oncology content.
The CTCA REVIEW Online Webcasts are intended for healthcare providers involved in the care of hematology and oncology patients, including medical oncologists, hematologists, radiation oncologists, radiologists, pathologists, oncology fellows, resident trainees, primary care providers, nurse practitioners, physician assistants, nurses, chiropractors, naturopathic physicians, and pharmacists.
After participating in each CTCA REVIEW Online Webcast, learners should be able to:
- Interpret new and emerging data presented at the ASH and ASCO annual conferences
- Incorporate newer evidence- based data to assess the care of their patients with cancer
- Incorporate knowledge gained into appropriate management strategies to improve outcomes in patients with cancer
- Utilize current standards of care for patients with cancer
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Dannemiller and Athena Education Group. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians.
Dannemiller designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Dannemiller is a provider approved by the California Board of Registered Nursing, Provider Number 4229 for 1.5 contact hours. RNs outside California must verify with their licensing agency for approval of this course.
Head and Neck Cancer
Ezra E.W. Cohen, MD
Department of Medicine
University of Chicago Medical School
Co-Director, Head and Neck Cancer Program
University of Chicago Comprehensive Cancer Center
Julie R. Gralow, MD
Professor and Director of Breast Medical Oncology
University of Washington School of Medicine and
Seattle Cancer Care Alliance
Member, Fred Hutchinson Cancer Research Center
Breast Cancer: Updates in Radiation Oncology
Dean Conterato, MD
Cancer Treatment Centers of America
Antoni Ribas, MD
Professor of Medicine, Professor of Surgery,
Professor of Molecular and Medical Pharmacology
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine, University of California Los Angeles (UCLA)
Los Angeles, CA
David H. Ilson, MD, PhD
Memorial Hospital for Cancer and Allied Diseases
Department of Medicine, Gastrointestinal Service
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University
NY Presbyterian, New York, NY
Maurie Markman, MD
Senior Vice President of Clinical Affairs
National Director of Medical Oncology
Cancer Treatment Centers of America
Jan C. Buckner
Professor of Oncology
Ramaswamy Govindan, MD
Professor of Medicine
Division of Medical Oncology
Washington University School of Medicine
Saint Louis, MO
Genitourinary Cancer- Novel Management Strategies and Updates
Ronald M. Bukowski, MD
Emeritus Staff Physician
Cleveland Clinic Taussig Cancer Center
Cleveland Clinic Foundation
GIST & Soft Tissue Sarcoma
Richard F. Riedel, MD
Assistant Professor, Division of Medical Oncology
Duke University Medical Center
Associate Director, Duke Sarcoma Program
Duke Cancer Institute
Genetic Testing in Familial Cancer Syndromes
James Ford, MD
Associate Professor of Medicine and Genetics
Division of Oncology
Director, Program for Clinical Cancer Genetics
Stanford University School of Medicine
Updates in Supportive Care Medicine
Michael J. Fisch, MD, MPH, FACP
Chair, Department of General Oncology
University of Texas MD Anderson Cancer Center
Jan C. Buckner, MD, has reported that he was a speaker and consultant/advisory board member for EMD Serono.
Ronald M. Bukowski, MD, has reported that he was a speaker for GlaxoSmithKline, Novartis, and Pfizer, and was a consultant/advisory board member for Argos Therapeutics, AstraZeneca, Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Vicus Therapeutics.
Ezra E.W. Cohen, MD, has reported that he was a consultant/advisory board member for Biocon and Vascular Biogenics.
Dean Conterato, MD, has reported no conflicts of interest.
Michael J. Fisch, MD, MPH, FACP, has reported no conflicts of interest.
James Ford, MD, has reported no conflicts of interest.
Ramaswamy Govindan, MD, has reported that he was a consultant/advisory board member for AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Covidien, Genentech, GlaxoSmithKline, and Pfizer.
Julie R. Gralow, MD, has reported that she was an investigator for Amgen, Genentech, Novartis, and Roche.
David H. Ilson, MD, PhD, has reported that he was an investigator for Bayer and Roche.
Maurie Markman, MD, has reported that he was a consultant/advisory board member for Genentech.
Antoni Ribas, MD, has reported that he was a consultant/advisory board member for Amgen, Celgene, GlaxoSmithKline, and Millenium Pharmaceuticals, and was an investigator for Bristol-Myers Squibb, Genentech, GlaxoSmithKline, and Millenium Pharmaceuticals.
Richard F. Riedel, MD, has reported that he was a speaker for Novartis and Pfizer, was a consultant/advisory board member for INC Research and Merck, and was an investigator for Astex Pharmaceuticals, Eisai, GlaxoSmithKline, INC Research, Infinity Oncology, Merck Novartis, and Threshold Pharmaceuticals.
Bernard Abrams, MD, content reviewer and Dannemiller Medical Director, has reported no conflicts of interest.
Michelle Montgomery, Dannemiller Director of Continuing Education, has reported no conflicts of interest.
Athena Education Group, LLC
Nike Gazonas, MS, has reported no conflicts of interest.
Shiva Noorchashm, has reported no conflicts of interest.
To resolve identified/potential conflicts of interest, the educational content was fully reviewed by a physician member of the Dannemiller Clinical Content Review Committee who have no financial relationships with commercial interests. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The faculty have been asked to disclose this information when presented. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, learners should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
The CTCA REVIEW is not an official program of ASH or ASCO, nor is it endorsed by ASH or ASCO. The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Dannemiller, Athena Education Group, or CTCA. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.
Jointly sponsored by Dannemiller Inc. and Athena Education Group, LLC
These activities are supported by an educational grant from Cancer Treatment Centers of America.
Method of Participation
To receive continuing education credit, participants should review all program materials in their entirety, complete and submit the online post-test and evaluation, and score at least 70% on the post-test. A statement of credit will be available for printing upon successful completion.
If you have any questions relating to the accreditation for this activity, please contact email@example.com.
If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.